Coronavirus the global pandemic: a guide to patenting
COVID-19 (short for coronavirus disease 2019) is caused by Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), more commonly referred to as coronavirus. Coronavirus has dominated world headlines in 2020, leading to nationwide...
COVID-19 (short for coronavirus disease 2019) is caused by Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), more commonly referred to...
Read More
Ramsay Health Care Investments Pty Limited [2020] ATMO 11 (30 January 2020)
Ramsay Health Care Investments Pty Limited (“Ramsay”) applied under Australian Trade Mark Application No. 1790252 to register the RAMSAY PHARMACY trade mark in respect of retailing services in Class 35 and pharmacy...
Ramsay Health Care Investments Pty Limited (“Ramsay”) applied under Australian Trade Mark Application No. 1790252 to register the RAMSAY PHARMACY trade...
Read More
Co-pack causes patent term extension problems for Patentee
Pharma Mar S.A. applied for a patent term extension (PTE) for their Australian patent 754073 on the basis of the listing on the Australian Register of Therapeutic Goods (ARTG) of the...
Pharma Mar S.A. applied for a patent term extension (PTE) for their Australian patent 754073 on the basis of the...
Read More
医療使用クレームの侵害への入り交じったメッセージおよび成功予測への数の付与
Mylan Health Pty Ltd (formerly BGP Products Pty Ltd) v Sun Pharma ANZ Pty Ltd (formerly Ranbaxy Australia Pty Ltd) FCA 28 (『 Mylan v Sun Pharma』) は薬物フェノフィブラートに関する3件の特許についての裁判事件です。フェノフィブラートは特に糖尿病患者において異常血中脂質を治療するために使用される医薬品です。これら特許のうち1件(オーストラリア特許第2006313711号、『711号特許』)は糖尿病性網膜症を治療するためのフェノフィブラートの使用に関し、他の2件の特許(豪州特許第731964号、『964号特許』および豪州特許第2003301807号(『807号特許』)はフェノフィブラートの組成物および製剤に関します。
Mylan Health Pty Ltd (formerly BGP Products Pty Ltd) v Sun Pharma ANZ Pty Ltd (formerly Ranbaxy Australia Pty...
Read More
Invention ownership and patents: the importance of written agreements
Patent rights for an invention can be challenged if ownership is not 'rock-solid'. Written agreements play an important role in determining ownership and patent rights to an invention, and use of the...
Patent rights for an invention can be challenged if ownership is not 'rock-solid'. Written agreements play an important role in determining...
Read More
Conference poster presentations as prior art for the assessment of novelty of a later patent application
Conferences are an important way for scientists and researchers to share and promote their research. They typically include poster presentation sessions where researchers present their findings. Conferences help generate interest in the scientific community...
Conferences are an important way for scientists and researchers to share and promote their research. They typically include poster presentation sessions...
Read More
オーストラリアにおける診断方法
Sequenom, Inc. v Ariosa Diagnostics, Inc. FCA 1011 において、連邦裁判所は、オーストラリアでは診断方法が特許可能であることを追認しました。これは、診断業界にとって満足の行く結果となりました。
Sequenom, Inc. v Ariosa Diagnostics, Inc. FCA 1011 において、連邦裁判所は、オーストラリアでは診断方法が特許可能であることを追認しました。これは、診断業界にとって満足の行く結果となりました。
Read More
New Zealand Update: Time to Examine Your Potential Patent Fees
Following our previous updates in November 2018 and April 2019, we now have certainty regarding patent fee increases in New Zealand.  Cabinet and the Executive Council of the New...
Following our previous updates in November 2018 and April 2019, we now have certainty regarding patent fee increases in...
Read More